Secondary Logo

Journal Logo

October 1, 2022 - Volume 91 - Issue 2

  • Paul A. Volberding, MD
    William A. Blattner, MD
  • 1525-4135
  • 1077-9450
  • 15 issues per year
  • Infectious Diseases 57/94
    Immunology 107/161
  • 3.771
Review of the Latest HIV/AIDS Treatment Experience in China: 2021-2022 Guest Editors: Fujie Zhang, Hongxin Zhao, Hui Wang, Qingxia Zhao, Shenghua He, Hongxia Wei, Renfang Zhang
Published October 1, 2022
Other Supplements

Current Issue Highlights




High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study

Beesham, Ivana; Parikh, Urvi M.; Mellors, John W.; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(2):130-137, October 1, 2022.


Pre-exposure Prophylaxis Discontinuation During the COVID-19 Pandemic Among Men Who Have Sex With Men in a Multisite Clinical Cohort in the United States

Goedel, William C.; Rogers, Brooke G.; Li, Yu; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(2):151-156, October 1, 2022.


Brief Report: Impact of COVID-19 on Cabotegravir Plus Rilpivirine Long-Acting Dosing Across 6 Ongoing Global Phase IIb and III Clinical Trials

Czarnogorski, Maggie; Benn, Paul; McCoig, Cindy; More

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(2):157-161, October 1, 2022.



Reply

Nosyk, Bohdan; Zang, Xiao; Krebs, Emanuel

JAIDS Journal of Acquired Immune Deficiency Syndromes. 91(2):e4-e5, October 1, 2022.

`